China's brain implant is already covered by insurance — Neuralink isn't even close

China just performed the world's first non-trial brain implant surgery — not as a research experiment, but as a standard medical procedure ordered by a physician. The operation took place at Huashan Hospital, affiliated with Fudan University in Shanghai, and used a device called NEO, approved by China's drug and medical device regulator (NMPA) in March 2026. Within days of that approval, NEO was assigned a reimbursement code inside China's national health insurance system, making it the first invasive brain-computer interface (BCI) anywhere in the world to reach covered, commercial medicine.

The patient and the device

The first commercial recipient had spent ten years unable to use his hands after a severe spinal cord injury from a car crash. Traditional rehabilitation had no fix: the physical "cable" carrying motor signals was severed. NEO, developed at Tsinghua University, works as a bypass. About the size of a coin, it sits on the dura mater — the membrane covering the brain — rather than penetrating brain tissue directly. That epidural placement puts it in a lower regulatory risk category than Neuralink's approach, which drives electrode threads into the cortex itself. The implant reads motor-intent signals from the brain and transmits them to an external robotic glove, which physically closes the patient's fingers when he thinks about gripping. Surgeons report the signal quality from the cortex came in higher than expected.

Where Neuralink stands

Neuralink, by contrast, has implanted 12 patients in the US under research protocols as of September 2025, per 3Zebras BCI Analysis. FDA commercial clearance is not expected before 2028–2030. Early Neuralink implants also ran into a thread-retraction problem — electrode threads pulled back from brain tissue in some patients — raising safety questions. There is no announced path to bring NEO to the US or UK market. If it ever did arrive, cost estimates for similar devices run between $40,000 and $70,000 per patient before any insurance offset.

China's scale ambitions

This is not a one-off. As MIT Technology Review reports, Beijing's five-year plan lists BCI as a strategic industry. Fudan University and partner institutions are already working to scale manufacturing. The target is geometric growth in procedure numbers by 2027, with full clinical deployment across China by 2030. The insurance integration — turning a six-figure surgery into a co-payment — is the part that has no Western equivalent yet. The US debate is still largely about whether the FDA will move faster; China has already moved.